



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Establishment of a novel human fetal adrenal culture model that supports de novo and manipulated steroidogenesis

Citation for published version:

Melau, C, Nielsen, JE, Perlman, S, Lundvall, L, Thuesen, LL, Hare, KJ, Hammerum, MS, Frederiksen, H, Mitchell, RT, Juul, A & Jørgensen, A 2020, 'Establishment of a novel human fetal adrenal culture model that supports de novo and manipulated steroidogenesis', *Journal of Clinical Endocrinology & Metabolism*.
<https://doi.org/10.1210/clinem/dgaa852>

Digital Object Identifier (DOI):

[10.1210/clinem/dgaa852](https://doi.org/10.1210/clinem/dgaa852)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Journal of Clinical Endocrinology & Metabolism

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



1 Establishment of a novel human fetal adrenal culture model that supports *de*
2 *novo* and manipulated steroidogenesis

3

4 Cecilie Melau^{a,b}, John E. Nielsen^{a,b}, Signe Perlman^c, Lene Lundvall^c, Lea Langhoff Thuesen^d, Kristine Juul
5 Hare^d, Mette Schou Hammerum^e, Hanne Frederiksen^{a,b}, Rod T. Mitchell^f, Anders Juul^{a,b}, and Anne
6 Jørgensen^{a,b*}

7

8 ^aDepartment of Growth and Reproduction, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen,
9 Denmark; ^bInternational Center for Research and Research Training in Endocrine Disruption of Male
10 Reproduction and Child Health, Rigshospitalet, DK-2100 Copenhagen, Denmark; ^cDepartment of
11 Gynaecology, University Hospital of Copenhagen (Rigshospitalet), DK-2100 Copenhagen, Denmark; and
12 ^dDepartment of Obstetrics and Gynaecology, Hvidovre University Hospital, DK-2650 Hvidovre, Denmark;
13 ^eDepartment of Obstetrics and Gynaecology, Herlev University Hospital, DK-2730 Herlev, Denmark, ^fMRC
14 Centre for Reproductive Health, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh
15 EH164TJ, United Kingdom

16

17 **Short title:** Human fetal adrenal *ex vivo* culture model

18

19 **Corresponding author:**

20 *Anne Jørgensen, PhD, Department of Growth and Reproduction, Copenhagen University Hospital,
21 Blegdamsvej 9, DK-2100 Copenhagen, Denmark.

22 **Phone:** +45 3545 8908,

23 **Email:** aj@rh.regionh.dk

24

25 **Keywords:**

26 steroidogenesis, androgen biosynthesis, *ex vivo* culture, endocrine activity, ACTH, Ketoconazole

27

28 **Grants and fellowships:** This work was supported by the International Center for Research and Research
29 Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), the Lundbeck
30 Foundation (PhD scholarship grant no. R249-2017-1484; to C.M.), the Novo Nordic Foundation (grant. No.
31 NNF19OC0056973; to A. Juul) and Aase and Ejnar Danielsen's Fund (to A. Jørgensen). MRC Centre for
32 Reproductive Health (R. T. Mitchell) is supported by MRC Centre Grant MR/N022556/1

33

34 **Disclosure Summary:** The authors have nothing to disclose.

35 **Abstract**

36 **Context:** Disorders affecting adrenal steroidogenesis promote an imbalance in the normally tightly controlled
37 secretion of mineralocorticoids, glucocorticoids, and androgens. This may lead to differences/disorders of sex
38 development in the fetus, as seen in virilized girls with congenital adrenal hyperplasia (CAH). Despite the
39 important endocrine function of human fetal adrenals, neither normal nor dysregulated adrenal steroidogenesis
40 is understood in detail.

41 **Objective:** Due to significant differences in adrenal steroidogenesis between human and model-species
42 (except higher primates), we aimed to establish a human fetal adrenal model that enables examination of both
43 *de novo* and manipulated adrenal steroidogenesis

44 **Design and Setting:** Human adrenal tissue from 54 1st trimester fetuses were cultured *ex vivo* as intact tissue
45 fragments for 7- or 14-days.

46 **Main Outcome Measure(s):** Model validation included examination of post-culture tissue morphology,
47 viability, apoptosis and quantification of steroid hormones secreted to the culture media measured by liquid
48 chromatography-tandem mass spectrometry.

49 **Results:** The culture approach maintained cell viability, preserved cell populations of all fetal adrenal zones,
50 and recapitulated *de novo* adrenal steroidogenesis based on continued secretion of steroidogenic
51 intermediates, glucocorticoids, and androgens. Adrenocorticotrophic hormone (ACTH) and ketoconazole
52 treatment of *ex vivo* cultured human fetal adrenal tissue resulted in the stimulation of steroidogenesis and
53 inhibition of androgen secretion, respectively, demonstrating a treatment-specific response.

54 **Conclusions:** Together these data indicate that *ex vivo* culture of human fetal adrenal tissue constitutes a
55 novel approach to investigate local effects of pharmaceutical exposures or emerging therapeutic options
56 targeting imbalanced steroidogenesis in adrenal disorders including CAH.

57 **Introduction**

58 During fetal life, human adrenal glands are highly active endocrine organs producing mineralocorticoids,
59 glucocorticoids, and androgens. In disorders such as congenital adrenal hyperplasia (CAH), mutations
60 affecting steroidogenic enzyme function cause an imbalance of the normally tightly controlled secretion of
61 adrenal steroids (1). The impaired enzyme function in CAH can occur at different steps in the adrenal
62 steroidogenesis pathway, resulting in a unique combination of elevated precursors and deficient products that
63 is strongly correlated to the clinical severity of the disorder (2). Excess of adrenal androgens during early
64 development can affect sexual differentiation of the fetus and manifest as virilized genitalia in girls with CAH.
65 Despite the importance of steroids secreted by human fetal adrenals (HFA) the development and endocrine
66 function of these organs are still relatively unexplored.

67

68 The morphology of the HFA gland is unique, initially consisting of a definitive zone (DZ) and a fetal zone (FZ).
69 The DZ, localized under the capsule of the organ, contains a thin layer of tightly packed basophilic cells, while
70 the remaining approximately 80 % of the gland consists of the inner FZ with large cells containing lipid-filled
71 vacuoles (3,4). DZ and FZ are distinguishable from about gestational week (GW) 7 while a third transitional
72 zone (TZ) containing intermediate ultrastructural characteristics emerges between the DZ and FZ during early
73 2nd trimester (3,5). Together, these three zones form the HFA cortex that express essential steroidogenic
74 enzymes in a distinct pattern and are responsible for the adrenal production of mineralocorticoids,
75 glucocorticoids and androgens throughout fetal development (3,5-12). Cells in the fetal adrenal cortex originate
76 from mesodermal adrenogenital primordium cells, but from around GW 7-8 migrating sympathoadrenal
77 progenitor cells with a neural crest origin reach the adrenal primordium (4,13,14). These cells secrete
78 catecholamines during fetal development and coalesce to form the inner medulla after birth (15). Interactions
79 between the fetal adrenal steroid-producing cortical cells and the catecholamine-secreting chromaffin cells are
80 crucial for cell differentiation, morphogenesis, and survival of the gland. Hence, dysregulated cross-talk
81 between the fetal adrenal cortical and chromaffin cells can affect regulation of hormone synthesis and stress
82 response, and can be involved in the pathogenesis of diseases that manifest in the adult adrenal glands (15-
83 17). Thus, alterations in the tightly regulated HFA steroidogenesis, catecholamine secretion, or fetal adrenal
84 cortical-medullary cell interaction may cause fetal endocrine dysfunction resulting in adrenal hypo- or
85 hyperplasia (4,15,16).

86

87 The endocrine function of HFAs and underlying mechanisms of congenital adrenal diseases are difficult to
88 investigate as morphology and steroid hormone profile of laboratory animal models (except higher primates)
89 differs from HFA glands (18,19). Several approaches have previously been used to study the endocrine
90 function of the HFA gland, predominantly as primary cell cultures of DZ and FZ cells obtained from HFA tissue
91 cultured separately or together (20-29). However, the lack of DZ-FZ and/or the cortical-chromaffin cell
92 interactions in single-cell suspensions is a limitation to these models. Additionally, a couple of approaches to
93 culture intact HFA tissue have previously been employed, but none of them have subsequently been used
94 systematically to determine their potential use in studies investigating HFA steroidogenesis (9, 30,31). The use
95 of a “hanging drop” approach has to our knowledge not previously been reported for culture of HFA tissue
96 fragments. This approach is effective in preserving functional integrity and signaling activity as shown from
97 differentiation of mouse embryoid bodies into different cell lineages (32,33) and has previously been used to
98 study manipulations of specific signaling pathways and pharmaceutical exposures in human fetal testis and
99 ovary (34-37). Therefore, in this study we aimed to test whether this culture approach could be applied to HFA
100 tissue (aged GW 8-11) in order to develop a model that recapitulates normal and dysregulated HFA
101 steroidogenesis and simultaneously support cell viability and tissue morphology.

102 **Material and Methods**

103 *Collection of human fetal adrenals*

104 The collection of human fetal adrenals in this study was approved by the Danish regional ethics committee
105 (permit number H-1-2012-007). Women were recruited to participate in the study by medical staff working
106 independently of the project and all women gave their informed written and oral consent. HFA tissue (GW 8-
107 11) was isolated from material available following elective surgical termination of pregnancy at Copenhagen
108 University Hospital (Rigshospitalet), Hvidovre Hospital, and Herlev Hospital, Denmark. None of the
109 terminations were for reasons of fetal abnormality or pathology of pregnancy. Fetal samples were kept at 4 °C
110 immediately after termination and during transportation to the laboratory. Fetal age was determined by
111 scanning crown-rump length and by evaluation of foot length (38). Fetal adrenal tissue was dissected in ice-
112 cold PBS and immediately set-up in *ex vivo* cultures. A total of 59 adrenals was used for *ex vivo* cultures,

113 corresponding to adrenals from 54 individual fetuses as both adrenals from the same fetus were occasionally
114 used for culture. Additionally, 8 intact adrenals from independent fetuses were formalin fixed immediately after
115 dissection and used as non-culture controls. Some of these adrenal control samples were also used as controls
116 in a previous study (5).

117

118 *Ex vivo human fetal adrenal tissue cultures*

119 Fetal adrenals were cultured *ex vivo* in “hanging drops” as described previously for human fetal gonad tissue
120 (34,36,37). In brief, all adrenals were divided into approximately 1 mm³ fragments prior to culture set-up. Fetal
121 adrenal tissue fragments were cultured in 40 µl medium for 7-14 days at 37°C under 5% CO₂ with complete
122 medium change every 48 hours. Media from all replicates of the same sample and treatment were collected
123 and pooled throughout the culture period of 7- or 14-days. Medium composition was: MEMα media
124 supplemented with 1x MEM non-essential amino acids, 2 mM sodium pyruvate, 2 mM L-glutamine, 1x Insulin,
125 Transferrin and Selenium (ITS) supplement, 1x Penicillin/Streptomycin, 10 % Fetal Bovine Serum (FBS). All
126 cell media and supplements were from Gibco (Naerum, Denmark), except ITS (Sigma-Aldrich, Broendby,
127 Denmark). To manipulate steroidogenesis, fetal adrenals were cultured in medium containing either 1 nM
128 ACTH dissolved in sterile H₂O, or 10 µM ketoconazole dissolved in dimethyl sulfoxide vehicle (DMSO, 0.1 %),
129 all reagents were from Sigma-Aldrich (Broendby, Denmark). ACTH concentration was chosen based on
130 previous studies reporting stimulation of fetal adrenal steroidogenesis at various concentrations below 3 nM
131 (21,30,39). Ketoconazole concentration was chosen based on inhibiting effects on steroidogenesis observed
132 in human fetal testis *ex vivo* cultures (40) and *ex vivo* cultured human fetal testis was treated with the same
133 stock of ketoconazole as a positive control. To ensure an equal relative ratio of DZ vs FZ cells were equal prior
134 to the experimental vehicle vs. treatment set-up, the adrenal gland was initially divided into two halves prior to
135 division into 1 mm³ fragments. Afterward, all fragments from one half of the gland was cultured in vehicle
136 control media and all fragments from the other half in treatment media, corresponding to 1-7 fragments per
137 treatment depending on the initial size of the HFA. Thus, one sample was always divided into an equal number
138 of vehicle control and treatment tissue fragments.

139

140 *Immunohistochemistry*

141 Fetal adrenal tissue was fixed in formalin either immediately after dissection (used as non-culture controls) or
142 at the end of the *ex vivo* culture period. The fixed adrenals were dehydrated, paraffin embedded and sectioned
143 (4 µm) using standard procedures. Serial sections of each sample were used for Immunohistochemistry (IHC)
144 as previously described for formalin-fixed samples (5). In brief, tissue sections were subjected to heat-induced
145 antigen retrieval buffer in a pressure cooker, and endogenous peroxidase was blocked with 3 % (v/v) H₂O₂ in
146 MeOH for 30 minutes. Between each step, sections were washed in Tris-buffered saline. Sections were
147 incubated in 5% BSA (w/v) in horse serum (20% v/v) ImmPRESS (Vector Laboratories, Burlingame, California)
148 for 30 minutes to minimize cross-reactivity. Primary antibodies were incubated overnight at 4°C followed by 1
149 hour at room temperature. Sections were incubated for 30 minutes with the appropriate ImmPRESS HPR
150 (peroxidase, Vector Laboratories, Burlingame, California) secondary antibody diluted in normal serum. Primary
151 antibodies, dilutions and retrieval buffers are listed in Table 1. Visualization was performed using ImmPACT
152 AEC peroxidase substrate (Vector Laboratories, Burlingame, California). Negative controls were included and
153 processed with the primary antibody replaced by the dilution buffer alone, none of which showed staining.
154 Sections were counterstained with Mayer's hematoxylin before mounting with Aquatex (Merck, Damstadt,
155 Germany). Sections were initially evaluated on a Nikon Microphot-FXA microscope and then by scanning slides
156 on a NanoZoomer 2.0 HT (Hamamatsu Photonics, Herrsching am Ammersee, Germany) followed by analysis
157 using the software NDPview software, version 1.2.36 (Hamamatsu Photonics, Herrsching am Ammersee,
158 Germany).

159

160 *BrdU incorporation assay*

161 BrdU incorporation was used to determine the presence of proliferating cells just prior to the end of the *ex vivo*
162 culture period as previously described (41). In brief, BrdU labeling reagent (Life Technologies, Naerum,
163 Denmark) was diluted in culture media and tissue fragments were placed in BrdU containing media for 6 hours
164 followed by fixation and paraffin embedding as described above. BrdU was visualized by IHC using a BrdU
165 antibody (Table 1) as described in the IHC section, with positively stained cells considered as proliferating.

166

167 *Immunohistochemical quantification*

168 IHC staining was used to quantitatively evaluate fetal adrenal tissue viability, zonation and expression of
169 steroidogenic enzymes after culture. The number of BrdU⁺ (proliferating) and cleaved PARP (cPARP⁺,
170 apoptotic) cells per mm² tissue were determined. IHC staining of CYP17A1 (steroidogenic enzyme), SPARC
171 (FZ marker) and NCAM-1 (DZ marker) expression were quantitatively assessed by measuring the area of
172 stained cells per total tissue fragment area. For each sample, the entire tissue section was quantified. All
173 tissue fragments originating from the same HFA gland were analyzed as replicates of one sample. Tissue area
174 was measured using NDPview software, version 1.2.36 (Hamamatsu Photonics, Herrsching am Ammersee,
175 Germany).

176

177 *Steroid hormone measurements in culture media*

178 Analysis of steroid hormone levels in culture media collected from the *ex vivo* culture experiments were
179 performed on pooled media samples from tissue fragments originating from the same sample and treatment
180 group collected during the entire culture period. Steroid hormone levels were measured using a method
181 established to quantify steroid metabolites in serum by isotype-dilution TurboFlow-LC-MS/MS as previously
182 described (42). The method was modified for measurement in culture media. This clinically validated analysis
183 package included estrone sulfate, testosterone, androstenedione, DHEAS, cortisone, cortisol, 11-
184 deoxycortisol, 17-hydroxyprogesterone, corticosterone, and progesterone. All measured metabolites except
185 estrone sulfate are reported in this study. In brief samples were analyzed in four batches during
186 summer/autumn of 2019, all including standards for calibration curves prepared in culture media, and for
187 method control; two blanks (water), two un-spiked culture media controls, two time two media culture controls
188 spiked with a mixture of native steroid standards in low and high concentration levels. For several of the
189 samples, the concentrations of dehydroepiandrosterone-sulfate (DHEAS), cortisol and cortisone were out of
190 the ordinary measurement range and were therefore diluted 1:10 with media and analyzed in a repeated batch.
191 For the four analytical batches included in this study the relative standard deviation (RSD) were < 10% for all
192 steroids in culture media controls spiked in low level, except for estrone sulfate and DHEAS (< 17%), and <
193 4.2% for all steroids in controls spiked in high level.

194

195 *Statistics*

196 Differences in percentages of immunopositive cells and steroid hormone concentrations were analyzed using
197 the Mann Whitney (two-tailed) u-test for comparison of 7- and 14-days cultures. Differences between treatment
198 and vehicle controls from the same HFA were analyzed using the Wilcoxon signed rank test (two tailed). All
199 statistical analysis was preformed using GraphPad Prism software. Asterisks indicate statistical significance
200 with *P<0.05, **P<0.01, ***P<0.001. Each sample value represents the mean value of all tissue fragments
201 originating from one sample and treatment group, and the number of replicates in each experiment is described
202 in the figure legends.

203

204 **Results**

205 *Ex vivo culture preserves HFA tissue morphology and cell viability*

206 To examine whether the *ex vivo* culture approach preserved tissue morphology, HFA fragments were analyzed
207 after 7- and 14-days of culture (Figure 1a). The overall morphology of the cultured HFA fragments was
208 maintained preserving both the DZ and FZ after both culture periods (Figure 1b). However, division of the
209 adrenal tissue into fragments (~1 mm³) and subsequent *ex vivo* culture did slightly alter the shape of the tissue
210 fragments which appeared more rounded. Thus, post-culture DZ cells were not restricted to the outer edge of
211 the tissue and FZ cells were not always restricted to the middle of the tissue fragments, but the specific cell
212 types always remained within zones after culture. Cell proliferation and apoptosis were examined after 7- and
213 14-days of culture, proliferation by BrdU incorporation and apoptosis by expression of cleaved PARP (cPARP)
214 (Figure 1c). The applied *ex vivo* culture approach supported continued cell proliferation as determined by BrdU
215 (Figure 1c) and Ki67 expression (Supplementary figure 1 (43)). Thus, both proliferating DZ and FZ cells were
216 detected, with DZ cells being the most frequently proliferating, which is in accordance with observations in the
217 non-culture control HFA tissue. Quantification of BrdU⁺ cells demonstrated no difference in the number of
218 proliferating (BrdU⁺ cells) between 7- and 14-days culture (Figure 1d). Overall, only few cPARP⁺ cells were
219 detected in both cultured and non-culture control HFA tissue (Figure 1c, Supplementary figure 1(43)). A small
220 increase in the prevalence of cPARP⁺ cells/mm² was observed in cultured tissue compared with non-culture
221 control HFA tissue, but the number of cPARP⁺ cells/mm² decreased with length of culture period (3.8-fold,

222 $p < 0.05$) when HFA tissue cultured for 14-days were compared to 7-days (Figure 1d). Together these results
223 suggest that the applied *ex vivo* culture approach supports HFA tissue for up to 14-days of culture with overall
224 preserved morphology, continued cell proliferation and a low level of apoptosis in the tissue.

225

226 *Steroidogenic activity is maintained after ex vivo culture of HFA tissue*

227 The endocrine function of *ex vivo* cultured HFA tissue was evaluated by steroidogenic protein expression and
228 secretion of steroid hormones. The examined steroidogenic enzyme expression was maintained after *ex vivo*
229 culture for 7- and 14-days. Thus, abundant expression of CYP17A1 and CYP11A1 were observed in FZ cells
230 in accordance with expression found in non-culture control samples (Figure 2a, Supplementary figure 2a (44)).
231 Overall, the zonation of the *ex vivo* cultured tissue was preserved containing both FZ cells (SPARC⁺, (21)) and
232 DZ cells (NCAM-1⁺, (45)) (Figure 2a). However, few areas of the cultured tissue fragments appeared negative
233 for DZ or FZ markers resulting in a 1.5-fold decrease ($p < 0.05$) in tissue positive for the HFA zonation markers
234 compared with non-culture controls (Figure 2b). This reduction did not appear to be dependent on the culture
235 period as no differences were observed between CYP17A1, SPARC or NCAM-1 expression between tissue
236 fragments cultured for 7- and 14-days (Supplementary figure 2b (44)). Additionally, analysis of the ratio
237 CYP17A1/SPARC expression suggested that CYP17A1 expression was similar to SPARC expression in the
238 *ex vivo* cultured tissue as well as in the non-cultured controls (Figure 2c). To clarify whether the cells negative
239 for both SPARC and NCAM-1 maintained expression of other proteins, the expression of steroidogenic factor
240 1 (SF-1) was examined. In non-culture controls and cultured HFA tissue SF-1 was expressed in DZ cells and
241 FZ cells (Supplementary figure 3 (46)), but no SF-1 expression was detected in areas of *ex vivo* cultured tissue
242 negative for SPARC and NCAM-1 (Supplementary figure 3b, dotted lines (46)). Some of the SF1-negative
243 cells morphologically resembled capsule cells, expected to be SF-1 negative, while others morphologically
244 resembled adrenal cortical cells suggesting that this sub-population of cells may have differentiated.
245 Importantly, the general steroidogenic activity of HFA tissue was maintained in *ex vivo* culture. Hence, the
246 secretion of androgens, glucocorticoids, and steroidogenic intermediates was consistent with no differences
247 in culture media concentrations between 7- and 14-days cultures (Figure 2d-f). The cultured HFA tissue
248 produced high amounts of both androgens and glucocorticoids. As anticipated DHEAS were by far the most
249 abundant of all measured metabolites ($>20,000$ nmol/L). The remaining steroid hormones measured in this
250 study followed the distribution of the intra-adrenal steroid hormones previously reported (47), with cortisol

251 (>1000 nmol/L) measured in the second highest concentrations (after DHEAS). In line with this, testosterone
252 (<5 nmol/L) levels were the lowest among the measured androgens but were still detectable in all samples. In
253 addition to the observed steroidogenic active fetal adrenal cortical cells, proliferating migrating neural crest
254 cells were also frequently observed in the tissue after 14-days culture (marked by NCAM-1 (48), Figure 3),
255 resembling the cell populations of non-cultured HFA controls.

256

257 *Steroidogenic activity can be both stimulated and inhibited in HFA tissue cultured ex vivo*

258 HFA tissue fragments were treated with ACTH (1 nM) or ketoconazole (10 μ M) to examine whether the
259 steroidogenic activity could be induced and inhibited in this *ex vivo* culture model (Figure 4a). The stimulating
260 effect of ACTH and inhibitory effect of ketoconazole on steroid hormone production was assessed after 7- and
261 14-days of culture. ACTH-treatment increased androgen, glucocorticoid, and steroidogenic intermediates
262 metabolite concentrations significantly compared with vehicle control treated samples after both culture
263 periods (Figure 4b, d). After 14 days of culture, ACTH treatment resulted in increased androgen levels,
264 including androstenedione (10.8-fold, $p<0.01$), testosterone (9.4-fold, $p<0.05$) and DHEAS (2.5-fold, $p<0.01$).
265 Also, glucocorticoid levels were increased after 14 days ACTH stimulation, including 17-hydroxyprogesterone
266 (4.5-fold, $p<0.01$), 11-deoxycortisol (12.7-fold, $p<0.01$), cortisol (6.9-fold, $p<0.01$) and cortisone (1.7-fold,
267 $p<0.01$). The steroidogenic intermediates progesterone (2-fold, $p<0.05$) and corticosterone (4.9-fold, $p<0.01$)
268 levels were also increased compared with vehicle controls. Treatment with ketoconazole resulted in decreased
269 secretion of androstenedione (1.8-fold, $p<0.05$) and DHEAS (4.2-fold, $p<0.01$) after culture for 14 days,
270 although this was only significant for DHEAS (1.7-fold, $p<0.05$) after 7 days of culture. Additionally, levels of
271 11-deoxycortisol (4.3-fold, $p<0.01$), 17-hydroxyprogesterone (2.3-fold, $p<0.05$) and progesterone (11.2-fold,
272 $p<0.01$) were all increased compared with vehicle controls as a result of ketoconazole treatment (Figure 4c,e).
273 Overall, the most pronounced effects on steroid hormone production were seen after 14 days of culture for
274 both ACTH and ketoconazole treatments.

275

276 The effects of ACTH and ketoconazole treatment on steroidogenic protein expression and HFA tissue zonation
277 were subsequently evaluated after 7- and 14-days of culture. Treatment with ACTH altered the composition of
278 HFA tissue, including an increased FZ-area (SPARC⁺ and CYP17A1⁺, both 3.5-fold increase, $p<0.05$ and
279 $p<0.01$, respectively) as well as a decreased DZ-area (NCAM-1⁺, 1.9-fold, $p<0.05$), compared with vehicle

280 controls after 14 days of culture (Figure 5). In contrast, no effect on FZ-area (SPARC⁺, CYP17A1⁺) or DZ-area
281 (NCAM-1⁺) was observed after 7- or 14-days culture with ketoconazole treatment (Supplementary figure 4
282 (49), Figure 5).

283

284 *Manipulation of steroidogenic activity does not affect morphology and cell viability of ex* 285 *vivo cultured HFA tissue*

286 Treatment with ACTH and ketoconazole did not alter the overall morphology of the *ex vivo* cultured HFA tissue,
287 which still contained all cell populations present in 1st trimester HFA tissue at the end of the culture period.
288 Effects of treatment on cell proliferation (BrdU) and apoptosis (cPARP) were examined after 7- and 14-days
289 culture (Figure 6a,b). No significant effects were detected on the number of proliferating (BrdU⁺) or apoptotic
290 (cPARP⁺) cells after treatment with ACTH or ketoconazole compared with vehicle controls (Figure 6c-d).
291 Proliferating cells were more frequently observed in DZ cells in *ex vivo* cultured samples regardless of
292 treatment but were also observed in FZ and neural crest cells in accordance with non-culture controls
293 (Supplementary figure 1 and Figure 3, respectively).

294 **Discussion**

295 In this study, an *ex vivo* tissue culture approach for HFA tissue has been established and validated. Thus, we
296 have shown that HFA tissue fragments can be cultured for 2 weeks with continued support of adrenal
297 morphology, cell proliferation and steroidogenic activity. Additionally, we demonstrated that this culture
298 approach allows inhibition and stimulation of the HFA tissues steroidogenic activity.

299

300 The *ex vivo* culture approach established in this study allows culture of HFA tissue for 14 days with continuing
301 proliferation with presence of only few apoptotic cells. Studies from the late 1970s reported that HFA tissue
302 fragments could be cultured *ex vivo* (0.5 cm³ on steel grids) for up to 14 days, however no details about
303 morphology or cell viability of the cultured tissue were reported (30,31). Also, long-term culture of HFA
304 organoids from primary cell cultures were recently reported, but necrotic core formation was observed after 10
305 days of culture (48). Thus, tissue fragments of approximately 1 mm³ used in this study seems to allow diffusion
306 of oxygen into the core of the fragments protecting the tissue from necrosis. In addition to continued

307 proliferation, the *ex vivo* culture approach used here preserved 1st trimester HFA morphology maintaining both
308 FZ, DZ and migrating neuroendocrine cells. Cross-talk between the different cell populations in HFA have been
309 shown to be important to ensure normal development of the adrenal gland (15,16). Hence, patients with CAH
310 due to 21-hydroxylase deficiency do not only have disrupted steroidogenesis, but the adrenal morphology is
311 also affected with poorly defined zonation and incomplete formation of the adrenal medulla, showing small
312 islands of chromaffin cells within the adrenal cortex (50). Accordingly, infants with CAH have reduced
313 adrenomedullary function (51). Thus, conserved cross-talk between the different adrenal cell-types are central
314 in the establishment of a culture model that aims to recapitulate normal and dysregulated HFA development
315 and function.

316
317 A small sub-population of cells in the cultured tissue fragment lost the expression of both FZ and DZ zonation
318 markers causing a slight reduction of the FZ-area in the cultured tissue compared with non-culture controls. At
319 least some of the difference in the quantification of zonation-area was due to the variation in orientation of the
320 paraffin embedded cultured tissue fragments. This variance made zonation-area quantification more
321 dependent on tissue orientation in *ex vivo* cultured tissue fragments compared with non-culture controls where
322 each tissue section represented a cross-section of an intact fetal adrenal gland. Therefore, zone-specific IHC
323 results should be considered as semi-quantitative. However, few small tissue areas lost expression of both
324 zonation markers and SF-1 which could indicate that this sub-population of cells are capsule cells with high
325 proliferation rate and/or adrenal cortical cells that have differentiated. The small affected areas did not increase
326 with a longer culture period suggesting that the *ex vivo* culture approach supports all cell populations up to 14
327 days. Overall, the presented HFA *ex vivo* culture approach preserved cell viability and an overall tissue
328 zonation that consisted of both neuroendocrine and steroidogenic cells.

329
330 The *ex vivo* culture approach described in this study supports the endocrine function of the HFA tissue. The
331 secreted steroid hormone profiles of androgens, glucocorticoids and steroidogenic intermediates from the
332 cultured tissue is in accordance with the intra-adrenal metabolites previously measured in un-cultured 1st
333 trimester HFA samples (5). Additionally, the high DHEAS levels secreted from the cultured HFA tissue in this
334 study is in accordance with DHEAS being the most abundant adrenal hormone produced during fetal life (52).
335 The continued production of androgens and glucocorticoids reported in this study contrasts with previous long-

336 term HFA tissue cultures which showed a rapid time-dependent decrease in the production of both DHEAS
337 and cortisol (30). Except for DHEAS and cortisol, the unstimulated steroid hormone production has not been
338 reported in any of the previously described tissue culture models. Thus, the presented HFA *ex vivo* approach
339 maintains a high steroidogenic activity which is a unique advance of this experimental approach while also
340 preserving FZ-specific abundant expression of steroidogenic enzymes. The *ex vivo* approach could therefore
341 be used to investigate the endocrine activity of the HFA gland in future studies that relate to understanding
342 HFA physiology in health and disease. This could include determination of *de novo* synthesis of HFA backdoor
343 androgen secretion as HFA tissue is able to convert steroid metabolites into backdoor pathway androgens (53)
344 which are suspected to play a crucial role in several congenital diseases including CAH (54-56).

345
346 Notably, we demonstrated that steroidogenic activity in *ex vivo* cultured HFA tissue can be stimulated and
347 inhibited resulting in altered profiles of classic steroid hormones. Thus, this provides proof-of-principle that this
348 culture approach can be used in future studies to examine effects on adrenal function following specific
349 treatments. ACTH stimulated the secretion of all measured metabolites, which is in accordance with previous
350 studies showing a stimulating effect on both cortisol, DHEAS, androstenedione and testosterone (9,30,31,39).
351 Interestingly, stimulation of steroid hormone secretion was accompanied by an increased FZ area and
352 CYP17A1 expression after culture for 14 days. This suggests that *ex vivo* cultured tissue responds in a similar
353 manner to HFA tissue *in vivo* as enlargement of the steroidogenic adrenal cortex is known to be a consequence
354 of hyperstimulated adrenals (57). Increased *CYP17A1* expression have also previously been reported in
355 response to ACTH (26). The enlarged FZ in ACTH stimulated tissue found in the present study after both 7-
356 and 14-days treatment could also explain the tendency towards a decreased number of proliferating cells since
357 DZ cells are known to have a higher proliferation rate than FZ cells (25).

358
359 Effects of the well-known inhibitor of steroidogenic enzymes, ketoconazole which affects multiple steps of
360 adrenal steroidogenesis was also examined in the HFA *ex vivo* model. Ketoconazole has different IC50 values
361 for each steroidogenic enzyme (58) and therefore some metabolites are expected to be upregulated while
362 metabolites downstream of these enzymes with the lowest IC50 values are expected to be downregulated in
363 a system where steroidogenesis is not completely inhibited. The observed inhibition of the HFA androgens
364 androstenedione and DHEAS following ketoconazole treatment for 14 days was therefore expected, as was

365 the increased levels of substrates for affected enzymes such as progesterone and 17-hydroxyprogesterone.
366 The overall lack of ketoconazole-mediated effects on corticosteroid levels was unexpected, especially the lack
367 of effect on cortisol secretion when compared with vehicle control samples. However, the increased
368 concentration of 11-deoxycortisol indicates that if the system had been pushed further either by initial ACTH
369 stimulation or higher ketoconazole concentrations an effect on cortisol might have been detectable. The higher
370 prevalence of 3 β HSD2⁺ cells/tissue area in 1st trimester compared with 2nd trimester HFA tissues and similar
371 intra-adrenal concentrations of corticosteroids (5) could suggest an elevated capacity for glucocorticoid
372 synthesis and subsequently a lower sensitivity towards inhibition of corticosteroid biosynthesis in 1st trimester
373 adrenal tissue. Accordingly, no effects were observed in the *ex vivo* cultured HFA tissue following treatment
374 with 1 μ M ketoconazole (Supplementary figure 5 (59)) and the used dose of 10 μ M ketoconazole in this study
375 is lower than expected *in vivo* ketoconazole serum concentrations in patients, as ketoconazole normally is
376 administrated in doses between 400-1200 mg/day (60) corresponding to ~12-25 μ M serum-ketoconazole
377 detected in patients 4-6 h after drug intake (61). Treatment effects of ketoconazole have previously been tested
378 in several primary cultures of human adrenocortical tissue and human adrenocortical carcinoma cell lines,
379 however the reported effects on steroid hormone production have been inconsistent depending on cell type
380 and dose (47,62-63). Thus, it is difficult to compare the effects of ketoconazole on the *ex vivo* cultured HFA
381 tissue composed of a heterogeneous cell population with previous studies. In this study, ketoconazole
382 treatment did not affect FZ-area (SPARC expression), expression of CYP17A1 in the cultured tissue or cell
383 viability compared with vehicle controls. This is in line with a previous study which found ketoconazole
384 concentrations below 10 μ M did not reduce cell viability of human adrenal carcinoma cells (61). Together these
385 data suggest that signaling pathways involved in the regulation of adrenal steroidogenesis are kept intact in
386 the *ex vivo* cultured tissue which retains the capacity to respond to both ACTH stimulation and ketoconazole
387 inhibition for up to 14 days. This specific steroidogenic response in the presented HFA *ex vivo* cultured tissue
388 suggest that this model can be used to investigate local effects of pharmaceutical exposures or emerging
389 therapeutic treatments that may impact adrenal development or function during pregnancy. Additionally,
390 manipulations of specific steroidogenic enzymes and cofactors in this model can serve as the foundation of a
391 human CAH *ex vivo* culture model allowing mechanistic studies of the dysregulated steroidogenesis in this
392 rare disease.

393

394 In conclusion, we have established an *ex vivo* culture approach for HFA tissue that allows culture for two weeks
395 with preserved adrenal morphology, cell viability, and a continued high steroidogenic activity. Investigations of
396 treatment effects in the HFA *ex vivo* cultures have demonstrated a specific response to both stimulation and
397 inhibition. Therefore, this model may be used to study both normal and dysregulated HFA steroidogenic activity
398 and function, which will be of particular relevance for understanding development and management of adrenal
399 disorders in humans.

400

401 **Acknowledgments**

402 The authors would like to thank staff members at the Departments of Gynecology (Rigshospitalet, Hvidovre
403 hospital and Herlev hospital) and Growth and Reproduction (Rigshospitalet) for help with the collection of fetal
404 tissue. The excellent technical assistance of Ana Ricci Nielsen, Brian Vendelboe Hansen, Katrine Harpelunde
405 Poulsen, Ole Nielsen, Stine Ehler and Camilla Tang Thomsen is gratefully acknowledged. Also, we are
406 grateful to all the women who participated in the study, without whom this study would not have been possible.

407

408 **Abbreviations**

409 ACTH: Adrenocorticotrophic hormone; CAH: Congenital adrenal hyperplasia; cPARP: Cleaved PARP; DZ:
410 Definitive zone; DHEAS: Dehydroepiandrosteron-sulfate; FZ: Fetal zone; GW: Gestational week; HFA: Human
411 fetal adrenals; IHC: Immunohistochemistry; LC-MS/MS: Liquid chromatography-tandem mass spectrometry;
412 RSD: Relative standard deviation; SEM: Standard error of the mean; TZ: Transitional zone.

413

414 **Data availability**

415 All data generated or analyzed during this study are included in this published article or in the data
416 repositories listed in references.

417

418 **Author Contributions**

419 C.M. and A. Jørgensen conceived and designed the experiments. C.M., J.E.N., and H.F. performed the
420 experiments. S.P., L.L., L.L.T., K.J.H., and M.S. provided study material. C.M., J.E.N., H.F., R.T.M., A. Juul,
421 and A. Jørgensen analyzed the data. C.M. and A. Jørgensen wrote the manuscript. All authors read and
422 approved the submitted version of the manuscript.

423

424 **References**

- 425 1. Bizzarri C, Olivini N, Pedicelli S, Marini R, Giannone G, Cambiaso P, Cappa M. Congenital primary
426 adrenal insufficiency and selective aldosterone defects presenting as salt-wasting in infancy: a single
427 center 10-year experience. *Ital J Pediatr.* 2015;42:1-8.
- 428 2. Hughes I. Congenital adrenal hyperplasia: phenotype and genotype. *J Pediatr Endocrinol Metab.*
429 2002;15:1329-1340.
- 430 3. Ishimoto H, Jaffe RB. Development and function of the human fetal adrenal cortex: A key component
431 in the fetoplacental unit. *Endocr Rev.* 2011;32:317-355.
- 432 4. Xing Y, Lerario AM, Rainey W, Hammer GD. Development of adrenal cortex zonation. *Endocrinol*
433 *Metab Clin N Am.* 2015;44:243-274.
- 434 5. Melau C, Nielsen JE, Frederiksen H, Kilcoyne K, Perlman S, Lundvall L, Langhoff Thuesen L, Juul
435 Hare K, Andersson AM, Mitchell RT, Juul A, Jørgensen A. Characterization of human adrenal
436 steroidogenesis during fetal development. *J Clin Endocrinol Metab.* 2019;104:1802-1812.
- 437 6. Mesiano S, Coulter CL, Jaffe RB. Localization of cytochrome P450 cholesterol side-chain cleavage,
438 cytochrome P450 17 α -hydroxylase/17, 20-lyase, and 3 β -hydroxysteroid dehydrogenase isomerase
439 steroidogenic enzymes in human and rhesus monkey fetal adrenal glands: Reappraisal of functional.
440 *J Clin Endocrinol Metab.* 1993;77:1184-1189.
- 441 7. Coulter CL, Jaffe RB. Functional maturation of the primate fetal adrenal in vivo: 3. Specific zonal
442 localization and developmental regulation of CYP21A2 (P450c21) and CYP11B1/CYP11B2
443 (P450c11/aldosterone synthase) lead to integrated concept of zonal and temporal steroid
444 biosynthesis. *Endocrinology.* 1998;139:5144-5150.

- 445 8. Narasaka T, Suzuki T, Moriya T, Sasano H. Temporal and spatial distribution of corticosteroidogenic
446 enzymes immunoreactivity in developing human adrenal. *Mol Cell Endocrinol.* 2001;174:111-120.
- 447 9. Goto M, Hanley KP, Marcos J, Wood PJ, Wright S, Postle AD, Cameron IT, Mason JI, Wilson DI,
448 Hanley NA. In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual
449 development. *J Clin Invest.* 2006;116:953-960.
- 450 10. Savchuk I, Morvan ML, Antignac JP, Gemzell-Danielsson K, Le Bizec B, Söder O, Svechnikov K.
451 Androgenic potential of human fetal adrenals at the end of the first trimester. *Endocr Connect.*
452 2017;6:348-359.
- 453 11. Naccache A, Louiset E, Duparc C, Laquerriere A, Patrier S, Renouf S, Gomez-Sanchez CE, Mukai K,
454 Lefebvre H, Castanet M. Temporal and spatial distribution of mast cells and steroidogenic enzymes in
455 the human fetal adrenal. *Mol Cell Endocrinol.* 2016;434:69-80.
- 456 12. Johnston ZC, Bellingham M, Filis P, Soffientini U, Hough D, Bhattacharya S, Simard M, Hammond
457 GL, King P, O'Shaughnessy JP, Fowler PA. The human fetal adrenal produces cortisol but no
458 detectable aldosterone throughout the second trimester. *BMC Med.* 2018;16:1-16.
- 459 13. Inoue S, Cho BH, Song CH, Fujimiya M, Murakami G, Matsubara A. Migration and distribution of neural
460 crest-derived cells in the human adrenal cortex at 9–16 weeks of gestation: an immunohistochemical
461 study. *Okajimas Folia Anat Jpn.* 2010;87:11-16.
- 462 14. Lumb R, Schwarz Q. Sympathoadrenal neural crest cells: The known, unknown and forgotten? *Dev*
463 *Growth Differ.* 2015;57:146-157.
- 464 15. Haase M, Willenberg HS, Bornstein SR. Update on the corticomedullary interaction in the adrenal
465 gland. *Endocr Dev.* 2011;20:28-37.
- 466 16. Schinner S, Bornstein SR. Cortical-chromaffin cell interactions in the adrenal gland. *Endocr Pathol.*
467 2005;16:91-98.
- 468 17. Parlato R, Otto C, Tuckermann J, Stotz S, Kaden S, Grone H, Unsicker K, Schutz G. Conditional
469 inactivation of glucocorticoid receptor gene in dopamine- β -hydroxylase cells impairs chromaffin cell
470 survival. *Endocrinology.* 2009;150:1775-1781.
- 471 18. Mesiano S, Jaffe RB. Role of growth factors in the developmental regulation of the human fetal adrenal
472 cortex. *Steroids.* 1997;62:62-72.

- 473 19. Abbott DH, Zhou R, Bird IM, Dumesic DA, Conley AJ. Fetal programming of adrenal androgen excess:
474 lessons from a nonhuman primate model of polycystic ovary syndrome. *Endocr Dev.* 2008;13:145-
475 158.
- 476 20. Ishimoto H, Ginzinger DG, Jaffe RB. Adrenocorticotropin preferentially up-regulates angiopoietin 2 in
477 the human fetal adrenal gland: Implications for coordinated adrenal organ growth and angiogenesis.
478 *J Clin Endocrinol Metab.* 2006;91:1909-1915.
- 479 21. Ishimoto H, Ginzinger DG, Matsumoto T, Hattori Y, Furuya M, Minegishi K, Tanaka M, Yoshimura Y,
480 Jaffe RB. Differential zonal expression and adrenocorticotropin regulation of secreted protein acidic
481 and rich in cysteine (SPARC), a matricellular protein, in the midgestation human fetal adrenal gland:
482 Implications for adrenal development. *J Clin Endocrinol Metab.* 2006;91:3208-3214.
- 483 22. Ishimoto H, Muench MO, Higuchi T, Minegishi K, Tanaka M, Yoshimura Y, Jaffe RB. Midkine, a
484 heparin-binding growth factor, selectively stimulates proliferation of definitive zone cells of the human
485 fetal adrenal gland. *J Clin Endocrinol Metab.* 2006;91:4050-4056.
- 486 23. Wang H, Huang M, Peng RX, Le J. Influences of 3-methylcholanthrene, phenobarbital and
487 dexamethasone on xenobiotic metabolizing-related cytochrome P450 enzymes and steroidogenesis
488 in human fetal adrenal cortical cells. *Acta Pharmacol Sin.* 2006;27:1093-1096.
- 489 24. Rehman KS, Sirianni R, Parker CR, Rainey WE, Carr BR. The regulation of adrenocorticotrophic
490 hormone receptor by corticotropin-releasing hormone in human fetal adrenal definitive/transitional
491 zone cells. *Reprod Sci.* 2007;14:578-587.
- 492 25. Ishimoto H, Minegishi K, Higuchi T, Furuya M, Asai S, Kim SH, Tanaka M, Yoshimura Y, Jaffe RB.
493 The periphery of the human fetal adrenal gland is a site of angiogenesis: Zonal differential expression
494 and regulation of angiogenic factors. *J Clin Endocrinol Metab.* 2008;93:2402-2408.
- 495 26. Xing Y, Parker CR, Edwards M, Rainey WE. ACTH is a potent regulator of gene expression in human
496 adrenal cells. *J Mol Endocrinol.* 2010;45:59–68.
- 497 27. Mansfield CW, Carr BR, Faye-Petersen OM, Chen D, Xing Y, Rainey WE, Parker CR. Differential gene
498 expression in the adrenals of normal and anencephalic fetuses and studies focused on the *fras-1*-
499 related extracellular matrix protein (*FREM2*) gene. *Reprod Sci.* 2011;18:1146-1153.
- 500 28. Agrawal V, Tee MK, Qiao J, Muench MO, Miller WL. Potential role of increased oxygenation in altering
501 perinatal adrenal steroidogenesis. *Pediatr. Res.* 2015;77:298-309.

- 502 29. Savchuk I, Morvan ML, Søbørg T, Antignac JP, Gemzell-Danielsson K, Bizec BL, Soder O,
503 Svechnikov K. Resveratrol inhibits steroidogenesis in human fetal adrenocortical cells at the end of
504 first trimester. *Mol Nutr Food Res.* 2017;61:1-8.
- 505 30. Goodyer CG, Hall CStG, Branchaud C, Giroud CJP. Exploration of the human fetal pituitary adrenal
506 axis: Stimulation of cortisol and dehydroepiandrosterone sulfate biosynthesis by homologous pituitary
507 in organ culture. *Steroids.* 1997;29:407-416.
- 508 31. Branchaud CT, Goodyer CG, Hall CStG, Arato JS, Silman RE, Giroud CJP. Steroidogenic activity of
509 hACTH and related peptides on the human neocortex and fetal adrenal cortex in organ culture.
510 *Steroids.* 1978;31:557-572.
- 511 32. Desbaillets I, Ziegler U, Groscurth P, Gassmann M. Embryoid bodies: An in vitro model of mouse
512 embryogenesis. *Exp Physiol.* 2000;85:645-651.
- 513 33. Koike M, Sakaki S, Amano Y, Kurosawa H. Characterization of embryoid bodies of mouse embryonic
514 stem cells formed under various culture conditions and estimation of differentiation status of such
515 bodies. *J Biosci Bioeng.* 2007;104:294-299.
- 516 34. Harpelunde Poulsen K, Nielsen JE, Frederiksen H, Melau C, Juul Hare K, Langhoff Thuesen L,
517 Perlman S, Lundvall L, Mitchell RT, Juul A, Rajpert-De Meyts E, Jørgensen A. Dysregulation of FGFR
518 signalling by a selective inhibitor reduces germ cell survival in human fetal gonads of both sexes and
519 alters the somatic niche in fetal testes. *Hum Reprod.* 2019;34:2228-2243.
- 520 35. Hurtado-Gonzalez P, Anderson RA, Macdonald J, van den Driesche S, Kilcoyne K, Jørgensen A,
521 McKinnell C, Macpherson S, Sharpe RM, Mitchell RT. Effects of exposure to Acetaminophen and
522 Ibuprofen on fetal germ cell development in both sexes in rodent and human using multiple
523 experimental systems. *Environ Health Perspect.* 2018;126:1-17.
- 524 36. Jørgensen A, Nielsen JE, Perlman S, Lundvall L, Mitchell RT, Juul A, Rajpert-De Meyts E. Ex vivo
525 culture of human fetal gonads: Manipulation of meiosis signaling by retinoic acid treatment disrupts
526 testis development. *Hum Reprod.* 2015;30:2351-2363.
- 527 37. Jørgensen A, Macdonald J, Nielsen JE, Kilcoyne KR, Perlman S, Lundvall L, Langhoff Thuesen L,
528 Juul Hare K, Frederiksen H, Andersson AM, Skakkebak NE, Juul A, Sharpe RM, Rajpert-De Meyts
529 E, Mitchell RT. Nodal signaling regulates germ cell development and establishment of seminiferous
530 cords in the human fetal testis. *Cell Rep.* 2018;25:1924-1937.

- 531 38. Evtouchenko L, Studer L, Spencer C, Dreher E, Seiler RW. A mathematical model for the estimation
532 of human embryonic and fetal age. *Cell Transplant*. 1996;5:453-464.
- 533 39. Serón-Ferré M, Lawrence CC, Siiteri PK, Jaffe RB. Steroid production by definitive and fetal zones of
534 the human fetal adrenal gland. *J Clin Endocrinol Metab*. 1978;47:603-609.
- 535 40. Mazaud-Guittot S, Nicolaz CN, Desdoits-Lethimonier C, Coiffec I, Ben Maamar M, Balaguer P,
536 Kristensen DM, Chevrier C, Lavoué V, Poulain P, Dejuq-Rainsford N, Jégou B. Paracetamol, aspirin,
537 and indomethacin induce endocrine disturbances in the human fetal testis capable of interfering with
538 testicular descent. *J Steroid Biochem Mol Biol*. 2011;125:23-31.
- 539 41. Jørgensen A, Young J, Nielsen JE, Joensen UN, Toft BG, Rajpert-De Meyts E, Loveland KL. Hanging
540 drop cultures of human testis and testis cancer samples: A model used to investigate activin treatment
541 effects in a preserved niche. *Br J Cancer*. 2014;110:2604-2614.
- 542 42. Søbørg T, Frederiksen H, Johannsen TH, Andersson AM, Juul A. Isotope-dilution TurboFlow-LC-
543 MS/MS method for simultaneous quantification of ten steroid metabolites in serum. *Clin Chim Acta*.
544 2017;468:180–186.
- 545 43. Melau C. Supplementary figure 1. October 2020. <https://doi.org/10.6084/m9.figshare.12789017.v3>
- 546 44. Melau C. Supplementary figure 2. October 2020. <https://doi.org/10.6084/m9.figshare.12788795.v5>
- 547 45. Muench MO, Ratcliffe JV, Nakanishi M, Ishimoto H, Jaffe RB. Isolation of definitive zone and
548 chromaffin cells based upon expression of CD56 (neural cell adhesion molecule) in the human fetal
549 adrenal gland. *J Clin Endocrinol Metab*. 2003;88:3921-3930.
- 550 46. Melau C. Supplementary figure 3. October 2020. <https://doi.org/10.6084/m9.figshare.13102886.v1>
- 551 47. Van der Pas R, Hofland LJ, Hofland J, Taylor AE, Arlt W, Steenbergen J, van Koetsveld PM, de Herder
552 WW, de Jong FH, Feelders RA. Fluconazole inhibits human adrenocortical steroidogenesis in vitro. *J*
553 *Endocrinol*. 2012;215:403-412.
- 554 48. Poli G, Sarchielli E, Guasti D, Benvenuti S, Ballerini L, Mazzanti B, Armignacco R, Cantini G, Lulli M,
555 Chortis V, Arlt W, Romagnoli P, Vannelli GB, Mannelli M, Luconi M. Human fetal adrenal cells retain
556 age-related stem- and endocrine-differentiation potential in culture. *FASEB J*. 2019;33:2263-2277.
- 557 49. Melau C. Supplementary figure 4. October 2020. <https://doi.org/10.6084/m9.figshare.12788981.v4>

- 558 50. Merke DP, Chrousos GP, Eisenhofer G, Weise M, Keil MF, Rogol AD, Van Wyk JJ, Bornstein SR.
559 Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. *N*
560 *Engl J Med.* 2000;343:1361-1368.
- 561 51. Kim MS, Ryabets-Lienhard A, Bali B, Lane CJ, Park AH, Hall S, Geffner ME. Decreased
562 adrenomedullary function in infants with classical congenital adrenal hyperplasia. *J Clin Endocrinol*
563 *Metab.* 2014;99:1597-1601.
- 564 52. Quinn T, Greaves R, Badoer E, Walker D. DHEA in prenatal and postnatal life: Implications for brain
565 and behavior. *Vitam Horm.* 2018;108:145-174.
- 566 53. Reisch N, Taylor AE, Nogueira EF, Asby DJ, Dhir V, Berry A, Krone N, Auchus RJ, Shackleton CHL,
567 Hanley NA, Arlt W. Alternative pathway androgen biosynthesis and human fetal female virilization.
568 *PNAS.* 2019;116:22294-22299.
- 569 54. Kamrath C, Hochberg Z, Hartmann MF, Remer T, Wudy SA. Increased activation of the alternative
570 "backdoor" pathway in patients with 21-hydroxylase deficiency: Evidence from urinary steroid hormone
571 analysis. *J Clin Endocrinol Metab.* 2012;97:367-375.
- 572 55. Jones CM, Mallappa A, Reisch N, Nikolaou N, Krone N, Hughes BA, O'Neil DM, Whitaker MJ,
573 Tomlinson JW, Storbeck KH, Merke DP, Ross RJ, Arlt W. Modified-release and conventional
574 glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia. *J Clin Endocrinol*
575 *Metab.* 2017;102:1797-1806.
- 576 56. Turcu AF, Nanba AT, Chomic R, Upadhyay SK, Giordano TJ, Shields JJ, Merke DP, Rainey WE,
577 Auchus RJ. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic
578 21-hydroxylase deficiency. *Eur J Endocrinol.* 2016;174:601-609.
- 579 57. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Endocr Rev.*
580 2000;21:245-291.
- 581 58. Fleseriu M, Castinetti F. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's
582 syndrome: a focus on novel therapies. *Pituitary.* 2016;9:643-653.
- 583 59. Melau C. Supplementary figure 5. October 2020. <https://doi.org/10.6084/m9.figshare.12789041.v2>
- 584 60. Braun LT, Reincke M. What is the role of medical therapy in adrenal-dependent Cushing's syndrome?
585 *Best Pract Res Clin Endocrinol Metab.* doi:10.1016/j.beem.2020.101376.

- 586 61. Sugar AM, Alsip SG, Galgiani JN, Graybill JR, Dismukes WE, Cloud GA, Craven PC, Stevens DA.
587 Pharmacology and toxicity of high-dose ketoconazole. *Antimicrob Agents Chemother.* 1987;31:1874-
588 1878.
- 589 62. Rijk JCW, Peijnenburg AACM, Blokland MH, Lommen A, Hoogenboom RLAP, Bovee TFH. Screening
590 for modulatory effects on steroidogenesis using the human H295R adrenocortical cell line: A
591 metabolomics approach. *Chem Res Toxicol.* 2012;25:1720-1731.
- 592 63. Creemers SG, Feelders RA, de Jong FH, Franssen GJH, de Rijke YB, van Koetsveld PM, Hofland LJ.
593 Osilodrostat Is a potential novel steroidogenesis inhibitor for the treatment of Cushing syndrome: An
594 in vitro study. *J Clin Endocrinol Metab.* 2019;104:3437-3449.

595 **Legends for figures and tables**

596

597 **Figure 1. Morphology and cell viability in human fetal adrenals cultured *ex vivo*.** (a) Experimental
598 overview of the *ex vivo* culture approach. (b-c) Morphology and expression pattern of BrdU (proliferation
599 marker) and cPARP (apoptosis marker) investigated on serial sections of fetal adrenal tissue cultured *ex vivo*
600 for 7- or 14-days. Counterstaining with Mayer's hematoxylin; scale bar corresponds to 100 μ m. Age of fetal
601 samples shown (at the start of experiment): 7 days culture (b+c) GW 10+1; 14 days culture (b+c) GW 9+2. (d)
602 Quantification of proliferating (BrdU⁺) and apoptotic (cPARP⁺) cells per mm² tissue. Values represent mean \pm
603 SEM, n = 7 fetuses for both culture periods. Values from the individual fetal samples are shown and represents
604 3-20 analyzed tissue fragments per fetal sample depending on the initial size of the adrenal gland. Significant
605 difference between 7- and 14-days cultures were analyzed using Mann Whitney (two-tailed) u-test, *p<0.05.
606

607 **Figure 2. Steroidogenic activity of human fetal adrenals cultured *ex vivo*.** (a) Expression of CYP17A1,
608 SPARC (fetal zone marker), and NCAM-1 (definitive zone marker) investigated on serial sections of intact 1st
609 trimester adrenal non-culture controls and fetal adrenal tissue cultured *ex vivo* for 7- or 14-days.
610 Counterstaining with Mayer's hematoxylin; scale bar corresponds to 100 μ m. Age of fetal samples shown (at
611 the start of experiment): non-culture control GW 11; 7 days culture GW 10+1, 14 days culture GW 10+4. (b)
612 Quantification of fetal- or definitive-zone tissue-area per mm² tissue was determined as the percentage of
613 SPARC and NCAM-1 expression, respectively. (c) Quantification of fetal-zone CYP17A1 expression was
614 determined as the ratio of CYP17A1/SPARC expression per mm² tissue. Values represent mean \pm SEM, non-
615 culture controls: n = 8 fetuses, *ex vivo* cultured tissue: n = 7 fetuses for both groups. Values from the individual
616 fetal samples are shown and represents 3-20 analyzed tissue fragments per fetal sample depending in the
617 initial size of the adrenal gland. Significant difference compared with non-culture controls were analyzed using
618 Mann Whitney (two-tailed) u-test, **p<0.01. (d-f) Quantification of secreted adrenal androgen, glucocorticoid,
619 and steroidogenic intermediates metabolites measured by LC-MS/MS (nmol/L) in culture media collected
620 throughout the experimental period of 7- or 14-days. Values represent mean \pm SEM; 7 days cultured tissue, n
621 = 7 fetuses; 14 days culture tissue, n = 11 fetuses, with media pooled from 3-20 tissue fragments per adrenal

622 depending on the initial size of the adrenal gland. Significant difference between 7- and 14-days cultures were
623 analyzed using Mann Whitney (two-tailed) u-test.

624

625 **Figure 3. Migrating neural crest cells are maintained in *ex vivo* cultured tissue.** Migrating neural crest
626 cells were frequently observed in *ex vivo* cultured tissue similar to non-cultured control tissue. (a) Expression
627 of NCAM-1 (definitive zone and neural crest cell marker) and CYP17A1 (fetal zone specific) in an intact 1st
628 trimester adrenal non-culture controls. (b) In addition to immunohistochemical staining of NCAM-1 and
629 CYP17A1, BrdU (proliferation marker) and cPARP (apoptosis marker) were investigated on serial sections of
630 fetal adrenal tissue cultured *ex vivo* for 14 days. Arrows indicate BrdU+ neural crest cells. Counterstaining with
631 Mayer's hematoxylin; scale bar corresponds to 50 μ m. Age of fetal samples shown (at the start of experiment):
632 non-culture control GW 10+6; 14 days culture GW 11+4.

633

634 **Figure 4. Manipulation of steroidogenesis in human fetal adrenals cultured *ex vivo*.** (a) Experimental
635 overview of *ex vivo* cultured human fetal adrenals treated with ACTH (1 nM) or ketoconazole (10 μ M) for 7- or
636 14-days. Quantification of secreted adrenal androgen, glucocorticoid, and steroidogenic intermediates
637 metabolites after ACTH or ketoconazole treatment. Secretion of adrenal steroid metabolites was measured by
638 LC-MS/MS in the culture media collected throughout the experimental period of 7- (b,c) or 14-days (d,e).
639 Quantification of secreted metabolite concentrations presented as a ratio relative to vehicle control samples.
640 Values represent mean \pm SEM, 7 days cultures: ACTH, n = 8 fetuses; ketoconazole, n = 10 fetuses; 14 days
641 cultures: ACTH, n = 9 fetuses; ketoconazole, n = 9 fetuses, with media pooled from 1-7 tissue fragments per
642 treatment depending on the initial size of half of the adrenal gland. Significant difference compared with vehicle
643 controls from the same HFA were analyzed using Wilcoxon matched-pairs signed rank test (two-tailed) t-test.,
644 *p<0.05, **p<0.01.

645

646 **Figure 5. Expression of CYP17A1 and zonation markers after manipulation of steroidogenesis in**
647 **human fetal adrenals cultured 14 days *ex vivo*.** (a) Effects of ACTH (1 nM) and ketoconazole (10 μ M)
648 treatment were examined by immunohistochemical staining for CYP17A1, SPARC (fetal zone marker), and
649 NCAM-1 (definitive zone marker) on serial sections of human fetal adrenals cultured *ex vivo* for 14-days.
650 Counterstaining with Mayer's hematoxylin; scale bar corresponds to 100 μ m. Age of fetal samples shown (at

651 the start of experiment): vehicle control 9+5; ACTH GW 9+2; ketoconazole GW 10+1. (b-c) Expression of
 652 CYP17A1, SPARC and NCAM-1 per mm² were quantified as a ratio relative to vehicle control samples. Values
 653 represent mean ± SEM, ACTH treated samples, n = 8 fetuses; ketoconazole treated samples n = 6 fetuses.
 654 Values from the individual fetal samples are shown and represents 1-7 analyzed tissue fragments per sample
 655 depending on the initial size of half of the adrenal gland. Significant difference compared with vehicle controls
 656 from the same HFA were analyzed using Wilcoxon matched-pairs signed rank test (two-tailed), *p<0.05,
 657 **p<0.01.

658

659 **Figure 6. Morphology and cell viability after manipulation of steroidogenesis in human fetal adrenals**
 660 **cultured *ex vivo*.** Morphology and expression pattern of BrdU (proliferation marker) and cPARP (apoptosis
 661 marker) investigated on serial sections of fetal adrenal tissue cultured *ex vivo* for 7- (a) or 14-days (b).
 662 Counterstaining with Mayer's hematoxylin; scale bar corresponds to 100 µm. Age of fetal samples shown (at
 663 the start of experiment): 7 days cultures: vehicle control GW 11+1; ACTH GW 9+4; ketoconazole GW 10+6,
 664 14 days cultures: vehicle control GW 10+2; ACTH GW 9+2; ketoconazole GW 10+1. (c-d) Quantification of
 665 proliferating (BrdU⁺) and apoptotic (cPARP⁺) cells per mm² determined as a ratio relative to vehicle control.
 666 Values represent mean ± SEM, 7 days cultures: ACTH, n = 5 fetuses; ketoconazole, n = 10 fetuses; 14 days
 667 cultures: ACTH, n = 8 fetuses; ketoconazole, n = 6 fetuses. Values from the individual fetal samples are shown
 668 and represents 1-7 analyzed tissue fragments per sample depending on the initial size of half of the adrenal
 669 gland. Significant difference compared with vehicle controls from the same HFA were analyzed using Wilcoxon
 670 matched-pairs signed rank test (two-tailed).

671

672 **Table 1.** Antibodies, dilutions and retrieval buffers used.

Antibody	Dilution	Retrieval buffer	Species	Supplier	Number
CYP11A1	1:10.000	TEG	Rabbit	Sigma	HPA016436
CYP17A1	1:1500	CIT	Rabbit	Abcam	Ab134910
SPARC	1:2000	CIT	Goat	R&D Systems	AF941
NCAM-1	1:1500	CIT	Mouse	BD Pharmingen	565237
BrdU	1:100	CIT	Mouse	Dako	M0744

cPARP	1:500	CIT	Rabbit	Cell Signaling	5625
Ki67	1:5000	TEG	Mouse	Dako	M7240
SF-1	1:10.000	CIT	Rabbit	Abcam	Ab217317

673

674 *Antigen retrieval was conducted by pressure cooking of the sections in indicated retrieval buffer for 30 min. in*
675 *a decloaking chamber. TEG buffer: 10 mM Tris, 0.5 mM EGTA, pH 9.0; Citrate (CIT) buffer: 10 mM, pH 6.0.*











